Announcement PDF RNS Number : 1728U Shield Therapeutics PLC 31 March 2021 Shield Therapeutics plc ("Shield" or the "Group") Block Listing 6 Monthly Return Date: 31 March 2021 Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: Period of return: From: Balance of unallotted securities under scheme(s) from previous return: Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not yet issued/allotted at end of period: Shield Therapeutics Retention Share Plan 01 October 2020 To: 31 March 2021 54,219 Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: Shield Therapeutics plc 2016 Company Share Option Plan 01 October 2020 To: 31 March 2021 388,079 Period of return: From: Balance of unallotted securities under scheme(s) from previous return: Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not yet issued/allotted at end of period: NIL -14,425 39,794 NIL NIL 388,079 Name of applicant: SHIELD THERAPEUTICS PLC Name of scheme: The Shield Therapeutics plc 2016 Long Term Incentive Plan 01 October 2020 To: 31 March 2021 Period of return: From: Balance of unallotted securities under scheme(s) from previous return: Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not yet issued/allotted at end of period: 171,883 Name of applicant: Name of scheme: SHIELD THERAPEUTICS PLC Shield Therapeutics Retention and Performance Share Plan 01 October 2020 To: 31 March 2021 1,885,819 Period of return: From: Balance of unallotted securities under scheme(s) from previous return: Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): Equals: Balance under scheme(s) not yet issued/allotted at end of period: NIL -147,610 24,273 2,500,000* -1,207,543 3,178,276 *Please note this number is further to the block listing applied for on the 24th March 2021 and admitted on 30th March 2021. This block listing has been allocated to the Shield Therapeutics Retention and Performance Share Plan in entirety. Name of contact: Telephone number of contact: Lucy Huntington-Bailey +44 (0) 191 511 8500 For further information, please contact: Shield Therapeutics plc Tim Watts (CEO) Lucy Huntington-Bailey, (Company Secretary and General Counsel) Peel Hunt LLP - Nominated Adviser & Joint Broker +44 (0) 191 511 8500 +44 (0) 20 7148 8900 James Steel / Christopher Golden finnCap Ltd - Joint Broker Geoff Nash / Alice Lane / Matthew Radley Walbrook PR - Financial PR & IR Adviser Paul McManus / Lianne Cawthorne +44 (0) 20 7220 0500 +44 (0) 20 7933 8780 or shield@walbrookpr.com About Shield Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END BLREADDFDSEFEFA